Charles Schwab Investment Management Inc. Has $4.50 Million Holdings in SI-BONE, Inc. (NASDAQ:SIBN)

Charles Schwab Investment Management Inc. boosted its stake in SI-BONE, Inc. (NASDAQ:SIBN) by 2.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 321,263 shares of the company’s stock after purchasing an additional 6,171 shares during the period. Charles Schwab Investment Management Inc.’s holdings in SI-BONE were worth $4,504,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of SIBN. VELA Investment Management LLC raised its position in shares of SI-BONE by 23.8% during the fourth quarter. VELA Investment Management LLC now owns 122,671 shares of the company’s stock worth $1,720,000 after acquiring an additional 23,592 shares during the last quarter. Versor Investments LP acquired a new stake in SI-BONE during the 4th quarter valued at approximately $185,000. Proficio Capital Partners LLC bought a new position in SI-BONE during the 4th quarter worth approximately $155,000. Impax Asset Management Group plc raised its holdings in SI-BONE by 1.1% during the 4th quarter. Impax Asset Management Group plc now owns 766,761 shares of the company’s stock worth $10,750,000 after purchasing an additional 8,240 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in shares of SI-BONE by 3.0% in the 4th quarter. Rhumbline Advisers now owns 57,621 shares of the company’s stock worth $808,000 after purchasing an additional 1,683 shares during the period. 98.11% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Anthony J. Recupero sold 3,670 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.90, for a total transaction of $51,013.00. Following the completion of the sale, the insider now directly owns 222,814 shares of the company’s stock, valued at $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Anshul Maheshwari sold 5,304 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total transaction of $73,778.64. Following the completion of the transaction, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. The trade was a 2.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 9,311 shares of company stock worth $130,356 in the last ninety days. Corporate insiders own 3.90% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Truist Financial reiterated a “buy” rating and set a $22.00 price objective (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Needham & Company LLC lifted their price objective on SI-BONE from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE has an average rating of “Buy” and an average price target of $24.50.

SI-BONE Trading Down 0.9 %

NASDAQ:SIBN opened at $14.68 on Wednesday. The firm has a fifty day simple moving average of $16.57 and a two-hundred day simple moving average of $14.79. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The stock has a market capitalization of $623.21 million, a price-to-earnings ratio of -15.96 and a beta of 1.17. The company has a current ratio of 8.25, a quick ratio of 7.22 and a debt-to-equity ratio of 0.22.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $49.00 million during the quarter, compared to analyst estimates of $48.87 million. Analysts expect that SI-BONE, Inc. will post -0.78 EPS for the current fiscal year.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.